If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ® (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How is the maintenance dose of subcutaneous Omvoh® (mirikizumab-mrkz) administered?
For maintenance dosing, mirikizumab is available as a prefilled pen or a prefilled syringe for subcutaneous administration. Patients may self-inject mirikizumab after being trained in subcutaneous injection technique.
Maintenance Dosing and Administration
Mirikizumab is intended for use under the guidance and supervision of a health care professional. Patients may self-inject mirikizumab after training in subcutaneous injection technique. Provide proper training to patients and caregivers on the subcutaneous injection technique of mirikizumab according to the “Instructions for Use” included with the packaged product.1
Maintenance Dosing Delivery Devices
Mirikizumab for the treatment of ulcerative colitis is available for subcutaneous injection as 100 mg/mL solution in a single-dose prefilled pen or a single-dose prefilled syringe.1
Recommended Maintenance Dose
The recommended maintenance dosage of mirikizumab for the treatment of ulcerative colitis is 200 mg administered by subcutaneous injection, given as 2 consecutive injections of 100 mg each, at week 12, and every 4 weeks thereafter.1
A full maintenance dose of mirikizumab will require 2 prefilled pens or 2 prefilled syringes given as 2 consecutive injections, in any order.1
The mirikizumab 200 mg/2 mL prefilled pen and 200 mg/2 mL prefilled syringe are only for maintenance treatment of Crohn’s disease.1
Injection Sites
Sites for injection include the abdomen, thigh, and back of the upper arm.1
Instruct patients to inject in a different location every time. For example, if the first injection was in the abdomen, administer the second injection - to complete a full dose - in another area of the abdomen, in the upper arm, or in the thigh. Administration of mirikizumab in the back of the upper arm may only be performed by another person.1
Do not inject into areas where the skin is
- tender
- bruised
- erythematous, or
- indurated.1
Preparation and Use
Before injection, remove mirikizumab prefilled pens or prefilled syringes from the refrigerator and leave at room temperature for 30 minutes.1
Do not shake the prefilled pens or syringes.1
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution should be a clear to opalescent, colorless to slightly yellow to slightly brown solution, and free of visible particles. Do not use mirikizumab if it is cloudy, discolored, or there are visible particles.1
Mirikizumab does not contain preservatives; therefore, discard any unused product. Do not reuse.1
Storage and Handling
Store mirikizumab refrigerated at 36°F to 46°F (2°C-8°C).1
Do not freeze mirikizumab and do not use mirikizumab if it has been frozen.1
Do not shake mirikizumab.1
Keep mirikizumab in the original carton to protect from light until the time of use.1
Discard any unused portion as mirikizumab is sterile and preservative-free.1
If needed, store the mirikizumab prefilled pen or prefilled syringe at room temperature up to 86°F (30°C) for up to 2 weeks in the original carton to protect from light. Do not return mirikizumab to the refrigerator once it has been stored at room temperature. Discard mirikizumab if these conditions are exceeded.1
The mirikizumab vial, prefilled pen, and prefilled syringe are not made with dry natural rubber latex.1
Enclosed Prescribing Information
Reference
1Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: February 24, 2025